Search | Clinical Trials Finder

Conditions: HIV Disease
Interventions: α1 Proteinase Inhibitor, Placebos; Biological · Drug
Lead sponsor: Institute for Human Genetics and Biochemistry; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Interventions: Alpha-1 MP; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 20 Years to 72 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 6
States / cities: Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more

Conditions: Cystic Fibrosis
Interventions: Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 10
States / cities: Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more

Conditions: Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions: Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions: SAR447537, Zemaira; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Alpha₁-Antitrypsin Deficiency
Interventions: Liquid Alpha₁-PI, Prolastin-C; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: alpha-1 proteinase inhibitor (human); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more

Conditions: COVID-19
Interventions: Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more

Conditions: Graft-Versus-Host Disease (GVHD) Acute on Chronic
Interventions: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alpha-1 Antitrypsin Deficiency, AATD
Interventions: INBRX-101/rhAAT-Fc; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Alpha-1 Antitrypsin Deficiency
Interventions: rAAV1-CB-hAAT; Drug
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Denver, Colorado • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Alpha 1 Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-PI; Drug · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more

Conditions: Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions: ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 6 Years to 35 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 28 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Alpha-1 MP, alpha-1 proteinase inhibitor (human); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Aralast NP, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 10 more

Conditions: Graft Versus Host Disease
Interventions: GLASSIA, methylprednisolone or equivalent steroid, Albumin; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: ADVM-043; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Charleston, South Carolina

Conditions: Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Interventions: Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Covid19, Pneumonia, Viral
Interventions: alpha1-proteinase inhibitor, Antiviral Agents; Drug
Lead sponsor: Blessing Corporate Services, Inc; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Hannibal, Missouri

Conditions: Alpha 1 Antitrypsin Deficiency
Interventions: Alpha-1 Antitrypsin (human); Drug
Lead sponsor: Michael Campos, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: KB408 (Nebulization); Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Gainesville, Florida • Charleston, South Carolina • The Woodlands, Texas

Search by objective public record fields.

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

GLASSIA Infusion Rate Study

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency